Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study

Trial Profile

Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
    • 22 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 15 Jan 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top